A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies

Background: Inhibition of p38 alpha mitogen activated protein kinase (p38α) has shown great promise as a treatment for Alzheimer's disease (AD) in preclinical tests. However, previous preclinical studies were performed in “pure” models of AD pathology. A vast majority of AD patients have comorbid de...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Hilaree N. Frazier, David J. Braun, Caleb S. Bailey, Meggie J. Coleman, Verda A. Davis, Stephen R. Dundon, Christopher J. McLouth, Hana C. Muzyk, David K. Powell, Colin B. Rogers, Saktimayee M. Roy, Linda J. Van Eldik
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2024-10-01
סדרה:	Brain, Behavior, & Immunity - Health
נושאים:	Alzheimer's disease VCID Hyperhomocysteinemia p38 MAPK Hippocampus neuroinflammation
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2666354624001042
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!